Collectively, our results demonstrate that tGLI1 and IL-6/IL-6R/GP130 signaling pathways are frequently co-overexpressed and co-activated and that co-activation is associated with worse MFS in HER2-enriched breast cancer and TNBC. Here, ERBB2 is linked to breast carcinoma.